Phenacemide Knowpia

Phenacemide
Clinical data
Trade names	Phenurone
AHFS/Drugs.com	Micromedex Detailed Consumer Information
ATC code	N03AX07 (WHO) ;
Pharmacokinetic data
Elimination half-life	22–25 hours
Identifiers
	IUPAC name N-Carbamoyl-2-phenyl-acetamide;
CAS Number	63-98-9 ;
PubChem CID	4753;
IUPHAR/BPS	7265;
DrugBank	DB01121 ;
ChemSpider	4589 ;
UNII	PAI7J52V09;
KEGG	D00504 ;
ChEMBL	ChEMBL918 ;
CompTox Dashboard (EPA)	DTXSID6023442 ;
ECHA InfoCard	100.000.519
Chemical and physical data
Formula	C9H10N2O2
Molar mass	178.191 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(NC(=O)N)Cc1ccccc1;
	InChI InChI=1S/C9H10N2O2/c10-9(13)11-8(12)6-7-4-2-1-3-5-7/h1-5H,6H2,(H3,10,11,12,13) ; Key:XPFRXWCVYUEORT-UHFFFAOYSA-N ;
	(verify)

Phenacemide (INN, BAN) (brand name Phenurone), also known as phenylacetylurea, is an anticonvulsant of the ureide (acetylurea) class.^[1] It is a congener and ring-opened analogue of phenytoin (a hydantoin),^[2]^[3] and is structurally related to the barbiturates and to other hydantoins.^[4] Phenacemide was introduced in 1949 for the treatment of epilepsy, but was eventually withdrawn due to toxicity.^[2]^[3]

References edit

^ Ganellin CR, Triggle DJ (21 November 1996). Dictionary of Pharmacological Agents. CRC Press. pp. 1578–. ISBN 978-0-412-46630-4.
^ ^a ^b Prasad JP (2010). "Central Nervous System". Conceptual Pharmacology. Universities Press. pp. 236–. ISBN 978-81-7371-679-9.
^ ^a ^b Saxena AK, Saxena M (1995). "Developments in anticonvulsants". In deStevens G, Zingel V, Leschke C, Hoeprich P, Schultz R, Mehrotra P, et al. (eds.). Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques. Vol. 44. Basel: Birkhäuser. pp. 185–291. doi:10.1007/978-3-0348-7161-7_6. ISBN 978-3-0348-7161-7. PMID 7644666. {{cite book}}: |journal= ignored (help)
^ Kadam SS, Mahadik KR, Bothara KG (1 July 2007). "Central Nervous System Depresants". Principles of Medicinal Chemistry. Vol. II. Pragati Books Pvt. Ltd. pp. 147–. ISBN 978-81-85790-03-9.